

March 25, 2025

Re. Infliximab Product Transition and New Claims Submission Procedure – Inflectra

Dear Health Care Provider,

Please be advised that on March 7, 2025, Health Canada authorized a name change for the Pfizer Canada ULC infliximab product Inflectra (DIN 02419475); moving forward, DIN 02419475 will be marketed and distributed as Remdantry (infliximab) by Celltrion Healthcare Canada, LTD.

Until September 30, 2025, DIN 02419475 will be commercially available as both Inflectra and Remdantry branded products. After this time, Inflectra will no longer be available on the Canadian market.

While DIN 02419475 is available as both Inflectra and Remdantry branded products, the department has assigned a PIN to Inflectra.

As of April 1, 2025 claims for Inflectra must be submitted using PIN 66128531, as outlined in the Claims Submission Procedure – Inflectra available here:

https://www.gov.mb.ca/health/pharmacare/profdocs/csp_inflectra.pdf

Questions regarding this infliximab product transition should be directed to Pfizer Canada ULC and Celltrion Healthcare Canada, LTD, through their Patient Support Programs (PSPs):

Inflectra – PfizerFlex Patient Support Program
Telephone: 1-855-935-FLEX (3539)
Email address: inflectra@pfizerflex.com

Remdantry – Celltrion Connect
Telephone number: 1-855-966-1648
Email address: support@celltrionconnect.ca

Sincerely,



Alan Lawless,
Executive Director
Non-Insured Benefits Branch